| Table Of Content |
Section I - Headache-related disability
1: Overview of headache prevalence, burden and management, Lipton, Scher & Stewart
2: Measuring headache disability, Scher, Lipton & Stewart
3: Benefits of treatment on headache disability - a personal view on selected data, Dahlöf
4: Comparing disability and psychological factors in migraine and transformed migraine, Magnusson & Becker
5: Cognitive efficiency following migraine therapy, Farmer, Cady, Reeves & Bleiberg
6: Comparative evolution of MIDAS score after monotherapy with triptans, Harmoussi-Peiglou, Dimitriadis & Vlachogianni
7: Disability-adjusted life years (DALYs) and MIDAS in Japan, Sakai, Igarashi & Iigaya
8: Disability in German headache sufferers: evaluation of a German headache disability inventory, Evers, Bauer, Gralow & Husstedt
9: MIDAS as a tool for monitoring the benefits of treatment strategies over time, Chauvet & MacGregor
10: The MIDAS questionnaire in children and young adolescents with headache: a pilot study, Grazzi, D'Amico, Andrasik, Usai, Leone, Rigamonti & Bussone
11: Relationship between disability and quality of life in migraine, D'Amico, Usai, Solari, Grazzi, Leone, Rigamonti & Bussone
12: Migraine in France in 2000: epidemiological data, Henry, Auray, Duru, Chazot, Dartigues, Lantéri-Minet, Lucas, Pradalier, El Hasnaoui & Gaudin
13: Validation of the Headache Impact Test (TM) using patient-reported symptoms and headache severity, Bjorner, Ware, Kosinski, Diamond, Tepper, Dowson, Bayliss & Batenhorst
14: Headache-related disability: discussion summary, Steiner
Section II - Patient-centred measures: health-related quality of life
15: Measuring health-related quality of life: general principles, Henry, Chrysostome, Michel & Dartigues
16: Effect of headache on quality of life, Terwindt, Ferrari & Launer
17: Assessment of the responsiveness of the Migraine-Specific Quality of Life Questionnaire (version 2.1), Martin, Pathak, Kwong, Batenhorst & Sharfman
18: Comparison of the impact of eletriptan versus sumatriptan on migraine-specific quality of life, Funk-Orsini, Miceli, Mackell & Wells
19: Impact of cluster headache on health-related quality of life, D'Amico, Rigamonti, Solari, Leone, Usai, Grazzi & Bussone
20: Improvement in migraine-specific quality of life with eletriptan (Relpax (TM)) as compared to Cafergot (R), Funk-Orsini, Miceli, Mackell & Wells
21: Improvements in health-related quality of life with long-term use of sumatriptan therapy for migraine, Burke, Kwong & Batenhorst
22: Psychometric evaluation of a computerised program to assess migraine-specific quality of life in clinical practice, Mannix, Kwong, Skinner & Dimsdale
23: Quality of life and disability in transformed migraine with drug overuse, D'Amico, Grazzi, Usai, Solari, Leone, Rigamonti & Bussone
24: Quality of life and migraine: a multicentre Spanish study, Láinez, Leira, Pascual, Díez Tejedor, Morales, Titus & Alberca
25: Patient-centred measures: health-related quality of life: discussion summary, Göbel
Section III - Family burden, comorbidities and health-care utilization
26: Family impact of migraine, Smith & Hasse
27: Migraine comorbidity with stroke, epilepsy and major depression, Breslau
28: Health care utilization for headache, Krogh Rasmussen
29: Functional improvement in migraine patients treated with oral eletriptan versus sumatriptan: a pooled analysis, Limmroth & Hettiarachchi
30: Health-care utilization for in-patient headache therapy, Göbel, Buschmann & Heinze
31: Self-described 'sinus headache' and headache related impact, Schreiber & Cady
32: Reducing the personal burden of migraine: a patient's perspective, Bülow-Olsen
33: The burden of migraine in a sample of doctors of an Italian general hospital in Rome, Catarci, Baldinetti & Granella
34: The Framig 2000 (II) survey: therapeutical data, Lucas, Lantéri-Minet & Chaffaut
35: The Framig 2000 (III) survey: health-care use, Lucas, Lantéri-Minet & Chaffaut
36: Family Burden, comorbidities and health-care utilization: discussion summary, Lipton
Section IV - Economics of headache
37: General principles of disease-costing, Jonsson
38: The economic burden of headache, Dartigues, Michel & Henry
39: Measuring the economic benefits of pharmacotherapy: general principles, Wells
40: Economic cost and benefit of pharmacotherapy for headache, Halpern
41: A stratified approach to migraine management including zolmitriptan is clinically and economically superior to step care approaches: results from the Disability in Strategies of Care (DISC) study, Charlesworth, Lipton & Stewart
42: A comparative study of the effectiveness of eletriptan, Cafergot (R) and sumatriptan in reducing the time loss associated with migraine attacks, Wells
43: The socio-economic impact of migraine in Spain, Láinez, Monzón & The Spanish Occupational Migraine Study Group
44: Reductions in medical and pharmacy resource utilization associated with the addition of preventive medication to the migraine management strategy, Silberstein, Winner & Chmiel
45: Utilization and price differentials of selective 5-HT1-receptor agonists in the European countries, Folino-Gallo, Palazzo, Stirparo, De Filippis & Martelletti
46: Regaining time lost during migraine attacks with eletriptan, Wells
47: Economics of headache: discussion summary, Olesen
Section V - Guidelines and interventions
48: Evidence-based guidelines for migraine headache, Silberstein
49: Model interventions to improve headache outcomes in health-care systems, Maizels
50: Model interventions to improve headache outcomes in the workplace, Stewart & Lipton
51: Analysis of headache patient's behaviour in the pharmacy: results of a French multicentre study, Mihout, Lantéri-Minet, Slama & Nachit-Ouinekh
52: Comparison of the efficacy of self-medication and medical prescriptions in reducing the burden of headache, Göbel, Petersen-Braun & Heinze
53: Evaluation of migraine in the workplace, Finkelstein, Berndt, Pransky & Mackell
54: Headache patient management in 21 Italian headache centres, Torelli & Manzoni
55: Migraine and chronic idiopathic headache in the French workforce: detection and management: the NOEMIE study protocol, Nachit-Ouinekh, El Amrani, El Hasnaoui & the National Orientation Committee
56: HIT-6 (TM) scores discriminate among headache sufferers differing in headache-associated workplace productivity loss, Bayliss, Kosinski, Diamond, Tepper, Garber, Ware & Batenhorst
57: Guidelines and interventions: discussion summary, Diener
Section VI - Improving health-care systems for headache
58: Integrating headache services across the primary/secondary care interface, Steiner
59: Comprehensive academic headache centres, Göbel
60: Headache clinic or pain centre: together or separate, Diener
61: The first year of the Lariboisière emergency headache centre: a series of 10510 patients, Valade, Ducros, El Amrani, Ben slamia, Roos, Djomby, Domigo, Morin, Besançon & Bousser
62: Headache symptoms and other headache features in non-specified headaches in primary care, Smith, Hasse, Richey, Cassedy & Rudawsky
63: Headache treatment outcome: a proposed paradigm for quantitative anaylsis, Borrell-Wilson & Cahill-Wright
64: Development of HIT-6 (TM), a paper-based short form for measuring headache impact, Bayliss, Bjorner, Kosinski, Dahlöf, Dowson, Cady, Ware & Batenhorst
65: Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway, Stovner, Hagen, Vattan, Zwart, Krokstad & Bovim
66: Reducing the burden of headache by communicating treatment strategies for employees, Göbel, Buschmann, Heinze, Püffel, Krüger, Meyer, Nicola & Polano
67: The usefulness of the publication Patient-centred strategies for effective management of migraine, in primary care, Cady, Farmer, Schreiber & Kaniecki
68: Improving health-care systems for headache: discussion summary, Silberstein
|
